Previously, we reported that CML patients with the BIM (Table 1) deletion polymorphism were at increased risk of experiencing inferior imatinib responses compared to those without [1]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.